Many patients with CLL are not receiving recommended first-line treatment with BTK inhibitors or BCL2 inhibitors, data suggest. Many patients with CLL are not receiving recommended first-line treatment with BTK inhibitors or BCL2 inhibitors, data suggest.
Results from a four-year follow-up of a phase 3 trial determined that the combination of Imbruvica and Venclexta provided benefits for untreated patients with CLL.
Pittsburgh-based oncology startup closes large funding round - Pittsburgh Business Times bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.